Sort
64,565 grants matching “drug discovery”
Light-Sheet Fluorescence Microscope
$477,301Heather Colleen Jensen-Smith · University Of Nebraska Medical Center · S10 · FY2021 · OD
Co-Targeting IL-6 and EGFRsignaling for the Treatment of Schwannomatosis and Associated Pain
$477,289Lei Xu · Massachusetts General Hospital · R01 · FY2023 · NS
Leads and Target Validation for Vascular Calcification in Chronic Kidney Disease
$477,232Jose Luis Millan · Sanford Burnham Prebys Medical Discovery Institute · RC1 · FY2010 · HL
Development and validation of a genetically engineered model of neurofibromatosis type 2 to facilitate discovery of neurotherapeutics
$477,230Joseph Kissil · Scripps Florida · R21 · FY2017 · NS
Characterization and targeting of leukemia stem cell metabolism
$477,177Craig T. Jordan · University Of Colorado Denver · R01 · FY2019 · CA
Markers of HIV Brain Disease under HAART: Validation in a Mouse Model
$477,160David J Volsky · St. Luke'S-Roosevelt Inst For Hlth Scis · R01 · FY2010 · MH
qHTS of Patient Derived HCC Models to Identify Novel Probes/Therapeutic Agents
$477,136Paul A. Johnston · University Of Pittsburgh At Pittsburgh · R01 · FY2020 · CA
UC San Diego Clinical and Translational Research Institute
$477,056Gary Steven Firestein · University Of California, San Diego · UL1 · FY2018 · TR
Novel Neurotensin Analogs as Antischizophrenics
$477,047Thomas A Dix · Argolyn Bioscience, Inc. · R44 · FY2006 · MH
Trypanosoma cruzi dormancy and its implications for therapeutic treatment
$477,009Rick L Tarleton · University Of Georgia · R01 · FY2021 · AI
Trypanosoma cruzi dormancy and its implications for therapeutic treatment
$477,009Rick L Tarleton · University Of Georgia · R01 · FY2020 · AI
Trypanosoma cruzi dormancy and its implications for therapeutic treatment
$477,009Rick L Tarleton · University Of Georgia · R01 · FY2024 · AI
Trypanosoma cruzi dormancy and its implications for therapeutic treatment
$477,009Rick L Tarleton · University Of Georgia · R01 · FY2023 · AI
Trypanosoma cruzi dormancy and its implications for therapeutic treatment
$477,009Rick L Tarleton · University Of Georgia · R01 · FY2022 · AI
GOALI: SusChEM: An industrial-academic collaboration for high throughput discovery of base metal catalysts
$477,000Paul J Chirik · Princeton University · · FY2013 · MPS
In Situ Natural Product Labeling and Applications
$477,000Wenjun Zhang · University Of California Berkeley · DP2 · FY2020 · AT
Annotating dark ion-channel functions using evolutionary features, machine learning and knowledge graph mining
$476,990Natarajan Kannan · University Of Georgia · U01 · FY2023 · CA
Personalized therapy for AATD-associated liver disease via IPS modeling
$476,963Andrew A Wilson · Boston University Medical Campus · R01 · FY2019 · DK
Personalized therapy for AATD-associated liver disease via IPS modeling
$476,963Andrew A Wilson · Boston University Medical Campus · R01 · FY2018 · DK
Personalized therapy for AATD-associated liver disease via IPS modeling
$476,963Andrew A Wilson · Boston University Medical Campus · R01 · FY2017 · DK
In Vitro Evaluation and Characterization of Novel Lead Therapeutic Candidates for Encephalitic Alphavirus Treatment
$476,935Donghoon Chung · University Of Tennessee Health Sci Ctr · U19 · FY2021 · AI
Membrane Protein Structure Using Evolutionary Couplings and Sparse NMR Data
$476,930Gaetano T Montelione · Rensselaer Polytechnic Institute · R01 · FY2019 · GM
Discovery and characterization of a novel natural product for the treatment of both diabetes and obesity
$476,912Dongmin Liu · Virginia Polytechnic Inst And St Univ · R01 · FY2025 · DK
KOR agonist functional selectivity in peripheral sensory neurons
$476,907William P Clarke · University Of Texas Hlth Science Center · R01 · FY2017 · DA
HER2-targeted exosomal delivery of therapeutic mRNA for enzyme pro-drug therapy
$476,899Ac Matin · Stanford University · UH2 · FY2015 · TR